4th October 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Cipla & Sun Pharma reach 52-week highs; Nifty Pharma outperforms benchmarks, rising 2%

Pharmaceutical company shares were in the spotlight as frontline stocks increased by up to 6% intraday on Monday as a result of a positive business outlook. Shares of Cipla reached a new high on the NSE of Rs 1,141.55, up 2%.

Zydus Lifesciences receives US FDA approval to manufacture and market Generic Drug

The US regulatory authority has granted an approval to Zydus Lifesciences US arm to manufacture the Generic version of ‘Mirabegron’ extended-release tablets of 25mg and 50mg with 180 days of shared generic drug exclusivity.

NPPA sets retail price of 40 drug formulations

According to a recent notice, the National Pharmaceutical Pricing Authority, Ministry of Chemicals and Fertilizers, Government of India, has set the retail price of 40 drugs new including drugs indicated for the treatment of high blood pressure, type 2 diabetes, bacterial infection and so on.

Kerala HC asks DoP to comment on unaffordability of patented Cancer drug

The Department of Pharmaceuticals (DoP) and a qualified officer of the Union Health Ministry have been ordered by the Kerala High Court to submit their responses regarding the affordability of the life-saving patented breast cancer drug Ribociclib within a month.

US FDA issues EIA to Lupin's Ankleshwar manufacturing unit

On Saturday, Lupin Limited disclosed that its Ankleshwar manufacturing facility in Gujarat, India, had received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA).

API manufacturing finally receiving the attention it deserves

Interesting trends are predicted for the Indian pharmaceutical industry in a recent Candle Partners report. The good news is that API manufacturing is finally getting the attention it deserves from promoters, private equity investors, and policymakers.

Diabetes leader USV lowers the cost of its well-liked diabetes drug JALRA OD

Leading pharmaceutical company USV Ltd. has now lowered the price of its brand JalraOD in an effort to make its popular antidiabetic medication more accessible to the Indian populace. The price has been reduced from Rs 18 per tablet to Rs 13.5 per tablet.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
1
Need Help?
PharmaState Academy
Hello, how can we help you?